← Back to Clinical Trials
Recruiting NCT06741137

NCT06741137 A Pilot Study of the Effect of the Combination of Inhaled Nitric Oxide and Prone Position Under EIT Monitoring on Efficacy in Patients with ARDS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06741137
Status Recruiting
Phase
Sponsor Northern Jiangsu People's Hospital
Condition ARDS
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2024-01-01
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
inhaled nitric oxide combined with prone position ventilation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2024-01-01 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Investigating the Impact of Combined Inhaled Nitric Oxide and Prone Positioning on the Efficacy in ARDS Patients

Eligibility Criteria

Inclusion Criteria: 1. Age 18-80 years; 2. Patients with moderate to severe ARDS on mechanical ventilation Exclusion Criteria: 1. Patients with severe asthma or acute exacerbation of chronic obstructive pulmonary disease (COPD), lung tumors, post-lung resection, and post-lung transplantation. 2. Patients with hemodynamic instability requiring vasopressor support: dopamine or dobutamine \>15 µg/kg/min, norepinephrine \>0.3 µg/kg/min. 3. Cardiogenic pulmonary edema. 4. Patients with severe facial deformities, facial trauma, or severe thoracoabdominal trauma that precludes prone positioning ventilation. 5. Mid to late pregnancy. 6. Patients with a history of malignancy or other irreversible diseases/conditions, including those in the terminal stage. 7. Patients expected to be discharged soon or requiring invasive mechanical ventilation for less than 24 hours. 8. Patients currently participating in other studies.

Contact & Investigator

Central Contact

Chuanqing Zhang Study Director

✉ 1504572590@qq.com

📞 1504572590

Frequently Asked Questions

Who can join the NCT06741137 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying ARDS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06741137 currently recruiting?

Yes, NCT06741137 is actively recruiting participants. Contact the research team at 1504572590@qq.com for enrollment information.

Where is the NCT06741137 trial being conducted?

This trial is being conducted at Yangzhou, China.

Who is sponsoring the NCT06741137 clinical trial?

NCT06741137 is sponsored by Northern Jiangsu People's Hospital. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology